Merck (MRK) Q4 Earnings and Revenues Beat Estimates

Core Insights - Merck reported quarterly earnings of $2.04 per share, exceeding the Zacks Consensus Estimate of $2.03 per share, and showing an increase from $1.72 per share a year ago, resulting in an earnings surprise of +0.62% [1] - The company achieved revenues of $16.4 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.33% and up from $15.62 billion year-over-year [2] - Merck's stock has increased by approximately 7.7% since the beginning of the year, outperforming the S&P 500's gain of 1.9% [3] Earnings Outlook - The future performance of Merck's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is $0.32 on revenues of $16.13 billion, and for the current fiscal year, it is $6.20 on revenues of $67.36 billion [7] Estimate Revisions - Prior to the earnings release, the estimate revisions trend for Merck was unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] Industry Context - The Large Cap Pharmaceuticals industry, to which Merck belongs, is currently ranked in the bottom 23% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Another company in the same industry, Eli Lilly, is expected to report quarterly earnings of $6.99 per share, reflecting a year-over-year increase of +31.4%, with revenues projected at $17.87 billion, up 32.1% from the previous year [9][10]